AML, Pre-leukaemic Clones and Precognition

Dr Chris Pallister, Managing Director of SciMed Consulting, offers his interpretation of two recent publications that provide an insight into how gene sequencing could be used to identify individuals at higher risk of developing AML, and could also predict which post-remission AML patients are most likely to relapse.  The role of non-random somatic mutations present […]

Read More…